

Additions and Corrections

2002, Volume 45

T. G. Murali Dhar,* Zhongqi Shen, Junqing Guo, Chunjian Liu, Scott H. Watterson, Henry H. Gu, William J. Pitts, Catherine A. Fleener, Katherine A. Rouleau, N. Z. Sherbina, Kim W. McIntyre, David J. Shuster, Mark R. Witmer, Jeffrey A. Tredup, Bang-Chi Chen, Rulin Zhao, Mark S. Bednarz, Daniel L. Cheney, John F. MacMaster, Laura M. Miller, Karen K. Berry, Timothy W. Harper, Joel C. Barrish, Diane L. Hollenbaugh, and Edwin J. Iwanowicz*: Discovery of *N*-[2-[2-[[3-Methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]-*N*-methyl-4-morpholineacetamide as a Novel and Potent Inhibitor of Inosine Monophosphate Dehydrogenase (IMPDH) with Excellent in Vivo Activity.

Page 2127. The author listing was incomplete. The correct list of authors is shown above.

Page 2129. The dose for compound **23** in Figure 4 (square icon) should be 100 mg/kg. The corrected figure is given below.




Figure 4. Treatment of adjuvant induced arthritis in rats with compound 23 ($p < 0.05$ vs vehicle, Student's *t* test). The graph depicts SEM for $n = 8$ rats per treatment.

JM020366H

10.1021/jm020366h

Published on Web 10/12/2002